What You Should Know:
– PGxAI, a pioneering leader in the field of AI-driven pharmacogenetics, today announced the launch of Deneb, its latest cutting-edge model poised to transform the landscape of drug development.
– Deneb is specifically designed to streamline this complex process by seamlessly integrating molecular structures, physicochemical properties, and comprehensive genetic profiles.
Drug Development for Biopharma
Tailored to meet the critical needs of biopharmaceutical companies and contract research organizations (CROs), Deneb delivers near real-time pharmacogenetic (PGx) recommendations. This capability promises to significantly reduce both the time and the substantial costs associated with clinical trials, while simultaneously increasing the probability of successful market entry for novel therapeutics.
By automating the traditionally labor-intensive process of PGx guideline creation, Deneb empowers researchers to precisely identify optimal patient cohorts for clinical trials. Furthermore, the model facilitates the refinement of drug dosing strategies and aids in the early anticipation of potential adverse drug reactions. The ultimate outcome is a more targeted and data-driven approach to drug development, which effectively mitigates the risk of trial failures and accelerates the journey of safer, more effective therapies to the patients who need them.
The development of Deneb is underpinned by PGxAI’s robust strategic partnerships with leading technology providers, including NVIDIA, InterSystems, Google, and Microsoft. These collaborations ensure seamless compatibility with existing research and development workflows within pharmaceutical organizations and CROs. By intelligently integrating data from a multitude of diverse sources, Deneb firmly positions PGxAI as a crucial ally for pharmaceutical innovators who are driven to shorten development timelines, minimize adverse events, and deliver groundbreaking therapies to patients across the globe.
“Clinical trial setbacks often stem from the wide variance in individual responses to drugs,” said Dr. Mike Zack, PGxAI co-founder and CEO. “Deneb tackles this challenge by leveraging AI and multi-omics data to rapidly predict how different patient groups will respond to a candidate drug — even before trials begin. This not only reduces costly trial failures but also expedites regulatory approvals.”
